Harvard
Christensen, MA, Fosbøl, EL, Bonde, AN, Olesen, JB, Gislason, GH, Torp-Pedersen, C & Gundlund, A 2020, '
Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study',
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, vol. 22, no. 5, pp. 716-723.
https://doi.org/10.1093/europace/euz340
APA
Christensen, M. A., Fosbøl, E. L., Bonde, A. N., Olesen, J. B., Gislason, G. H., Torp-Pedersen, C., & Gundlund, A. (2020).
Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
22(5), 716-723.
https://doi.org/10.1093/europace/euz340
CBE
Christensen MA, Fosbøl EL, Bonde AN, Olesen JB, Gislason GH, Torp-Pedersen C, Gundlund A. 2020.
Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 22(5):716-723.
https://doi.org/10.1093/europace/euz340
MLA
Vancouver
Author
Christensen, Mathias Aagaard ; Fosbøl, Emil Loldrup ; Bonde, Anders Nissen ; Olesen, Jonas Bjerring ; Gislason, Gunnar H ; Torp-Pedersen, Christian ; Gundlund, Anna. /
Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease : a nationwide cohort study. In:
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2020 ; Vol. 22, No. 5. pp. 716-723.
Bibtex
@article{2e77b691c8ed401a97416d1f4ec7e146,
title = "Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study",
abstract = "AIMS: Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke.METHODS AND RESULTS: We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71-83) and 80 (IQR 72-86), respectively]. The median follow-up period was 1.9 years (IQR 0.8-3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73-1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67-1.17).CONCLUSION: Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.",
keywords = "Chronic kidney disease, Ischaemic stroke, Oral anticoagulation therapy, Secondary prevention, Stroke prevention",
author = "Christensen, {Mathias Aagaard} and Fosb{\o}l, {Emil Loldrup} and Bonde, {Anders Nissen} and Olesen, {Jonas Bjerring} and Gislason, {Gunnar H} and Christian Torp-Pedersen and Anna Gundlund",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.",
year = "2020",
month = may,
day = "1",
doi = "10.1093/europace/euz340",
language = "English",
volume = "22",
pages = "716--723",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "5",
}
RIS
TY - JOUR
T1 - Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease
T2 - a nationwide cohort study
AU - Christensen, Mathias Aagaard
AU - Fosbøl, Emil Loldrup
AU - Bonde, Anders Nissen
AU - Olesen, Jonas Bjerring
AU - Gislason, Gunnar H
AU - Torp-Pedersen, Christian
AU - Gundlund, Anna
N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - AIMS: Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke.METHODS AND RESULTS: We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71-83) and 80 (IQR 72-86), respectively]. The median follow-up period was 1.9 years (IQR 0.8-3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73-1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67-1.17).CONCLUSION: Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.
AB - AIMS: Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke.METHODS AND RESULTS: We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71-83) and 80 (IQR 72-86), respectively]. The median follow-up period was 1.9 years (IQR 0.8-3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73-1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67-1.17).CONCLUSION: Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.
KW - Chronic kidney disease
KW - Ischaemic stroke
KW - Oral anticoagulation therapy
KW - Secondary prevention
KW - Stroke prevention
U2 - 10.1093/europace/euz340
DO - 10.1093/europace/euz340
M3 - Journal article
C2 - 31872246
VL - 22
SP - 716
EP - 723
JO - Europace
JF - Europace
SN - 1099-5129
IS - 5
ER -